Immune Globulin: A Guide to Billing and Reimbursement
Billing for reimbursement of this costly, lifesaving therapy can be complicated, but for the sake of the provider and the patient, getting it right the first time can shorten approval time and prevent denials.
Infusion Environments: Comparing Costs, Safety and Privacy
When choosing a site of care for immune globulin therapy, each patient’s unique situation needs to be considered.
Intravenous Immunoglobulin Protects Neurons Against Amyloid Beta-Peptide Toxicity: In Vitro and Murine Studies
A multinational team of investigators exposed cultured neurons with intravenous immunoglobulin (IVIG) to evaluate its effect on downstream signaling pathways involved in neuronal cell death.
Slow Release of IG May Delay Alzheimer’s Disease
Recent studies suggest that the divergent outcomes in Alzheimer’s disease clinical studies of intravenous immune globulin (IVIG) may be due to differences in temporal administration and administered dosages.
Biotest’s Investigational 10% Liquid IVIG Assessed in Patients with PIDD
An investigational 10% liquid intravenous immunoglobulin product currently under U.S. regulatory review for marketing approval appears to be safe and effective for prophylactic treatment of patients with primary immunodeficiency disorders.
Immunotherapy May Help to Treat Alzheimer’s
Canadian scientists are working on an intravenous treatment for Alzheimer’s that could halt the progression of the disease and improve cognitive functions.
Lifelong Need for IG? Weighing the Pros and Cons
There is some debate among immunologists as to whetherIG therapy prescribed to treat adults diagnosed with immunedeficiencies should be temporarily halted to determine its necessity.Here, two experts present their sides of the issue.
Immune Globulin Therapy: The Investigational Frontier
IG is being successfully studied to treat more diseases than ever before, especially for hematological, neurological and autoimmune conditions.
Individual IG Dosing
Studies that examine the relationships between therapeutic doses of IG, trough IgG levels and infection rates shed new light on how IG replacement therapy should be prescribed for individuals.
Immune Globulin Reimbursement
A high-cost therapy coupled with a complex and evolving reimbursement model has created what some are calling a healthcare crisis for tens of thousands of chronically ill patients.